Arkolith/Insider Trading/TARS/Form 4

Farrow Jeffrey S

See RemarksTarsus Pharmaceuticals, Inc. (TARS) · full profile →Form 4 · filed Jun 17, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$877K
Net Open-Market Flow
-$877K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 16, 2026Sell(S)14K$60.95$877K57K
Jun 15, 2026Option exercise(M)28K——71K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 15, 2026Option exercise(M)28K—$028K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001405253-26-000013) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML